Novel strategies for targeting the thioredoxin system for cancer therapy.
Qianhe XuJunmin ZhangPublished in: Expert opinion on drug discovery (2022)
The limited pharmacophore of inhibitors and the slow progress of clinical research partially restrict the development of anticancer drugs targeting the thioredoxin system, necessitating thus novel strategies to accelerate the system for treating cancer. Nevertheless, the synergistic targeting of thioredoxin system for cancer therapy is a promising strategy, particularly with regards to chemotherapy resistance and/or sensitization immunotherapy.